About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Oxytocin in MRI-HIFU

Clinicaltrials.gov identifier NCT03937401

Recruitment Status Enrolling by invitation

First Posted May 3, 2019

Last update posted May 3, 2019

Study Description

Brief summary:

Capability of oxytocin in improving the efficacy of MRI-HIFU is studied. Patients undergoing MRI-HIFU treatment are given oxytocin during treatment and the efficacy of the treatment will be analysed by patient reported symptom questionnaires and imaging data.

  • Condition or Disease:Fibroid
  • Intervention/Treatment: Drug: Oxytocin
  • Phase: Phase 4
Detailed Description


Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Use of Oxytocin in MRI-HIFU Treatment
  • Actual Study Start Date: February 2019
  • Estimated Primary Completion Date: December 2019
  • Estimated Study Completion Date: January 2021
Arms and interventions
Arm Intervention/treatment
Experimental: Patients treated with oxytocin during MRI-HIFU
Drug: Oxytocin
Oxytocin infusion during MRI-HIFU treatment
Outcome Measures
  • Primary Outcome Measures: 1. NPV [ Time Frame: up to one year ]
    non perfused volume (percentage of fibroid destroyed)
  • 2. duration of MRI-HIFU [ Time Frame: up to one year ]
    duration of MRI-HIFU treatment
  • 3. UFS-Qol [ Time Frame: 12 months after HIFU treatment ]
    Uterine fibroid symptom severity and quality of life (patient quality of life questionnaire)
Eligibility Criteria
  • Ages Eligible for Study: 18 to 50 Years (Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: Yes

Inclusion Criteria:

- Patients undergoing MRI-HIFU -treatment

- Patients assessed for suitability to MRI-HIFU treatment

- willingness to participate in trial

Exclusion Criteria:

- Known allergy to Syntocinon/oxytocin

- Elevated blood pressure

- ischemic heart disease

- Long QT- interval

Contacts and Locations

Turku University Hospital

Sponsors and Collaborators

Turku University Hospital

More Information
  • Responsible Party: Turku University Hospital
  • ClinicalTrials.gov Identifier: NCT03937401 History of Changes
  • Other Study ID Numbers: T366/2017
  • First Posted: May 3, 2019 Key Record Dates
  • Last Update Posted: May 3, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing
  • Plan to Share IPD: No
  • Plan Description: Individual participant data will not be shared with other researchers
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by Turku University Hospital: fibroid
  • Additional relevant MeSH terms: Leiomyoma Adenomyosis